Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kezar Life Sciences Inc (NQ: KZR ) 0.6287 +0.0174 (+2.85%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Kezar Life Sciences Inc < Previous 1 2 3 4 5 6 Next > Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug August 14, 2024 Kezar Life Sciences announced it has stopped enrollment in its phase 1 solid tumor drug study and will focus on developing zetomipzomib for autoimmune diseases. Via Benzinga KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024 August 13, 2024 KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update August 13, 2024 From Kezar Life Sciences, Inc. Via Business Wire Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) July 10, 2024 From Kezar Life Sciences, Inc. Via Business Wire Analyst Expectations for Kezar Life Sciences's Future November 27, 2023 Via Benzinga Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) June 07, 2024 From Kezar Life Sciences, Inc. Via Business Wire Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference May 29, 2024 From Kezar Life Sciences, Inc. Via Business Wire KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024 May 09, 2024 KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Kezar Life Sciences, Inc. Via Business Wire Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 06, 2024 From Kezar Life Sciences, Inc. Via Business Wire Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) April 08, 2024 From Kezar Life Sciences, Inc. Via Business Wire From Pennies to Fortunes: 3 Stocks Set to Make Millionaires March 27, 2024 Discover how these stocks to make millionaires are leading in the gold, biotechnology, and application software industries. Via InvestorPlace Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026 March 16, 2024 Learn how these penny stocks may yield a 5X return with their lead in application software and biotechnology. Via InvestorPlace KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023 March 14, 2024 KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update March 14, 2024 From Kezar Life Sciences, Inc. Via Business Wire Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) March 08, 2024 From Kezar Life Sciences, Inc. Via Business Wire Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal March 02, 2024 Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... Via Talk Markets Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference February 28, 2024 From Kezar Life Sciences, Inc. Via Business Wire Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis February 26, 2024 From Kezar Life Sciences, Inc. Via Business Wire 3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond February 25, 2024 When you want to light your afterburners, these ideas will do the trick. Via InvestorPlace 3 Penny Stocks Poised for an Unbelievable 1,000% Jump February 02, 2024 Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await. Via InvestorPlace As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits January 08, 2024 Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining. Via Benzinga Topics Initial Public Offering Exposures Securities Market Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth December 18, 2023 Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth. Via InvestorPlace Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update November 13, 2023 From Kezar Life Sciences, Inc. Via Business Wire Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) November 03, 2023 From Kezar Life Sciences, Inc. Via Business Wire 10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis October 23, 2023 Via ACCESSWIRE Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) October 09, 2023 From Kezar Life Sciences, Inc. Via Business Wire Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer October 03, 2023 From Kezar Life Sciences, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023 October 05, 2023 Via Benzinga Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement September 23, 2023 Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... Via Talk Markets < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.